BWI-CTU

Immune Correlates of LTBI in HIV-exposed Infants

Post Date: 
2019-04-29
   |   
Countries: 
About 2 billion people worldwide harbor asymptomatic latent TB infection (LTBI), activation of which results in progression to TB disease. In areas of high tuberculosis (TB) prevalence, infants and young children have a 3-fold higher risk of progression and death from TB at age < 5 years...

P2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants “VESTED”

Post Date: 
2019-02-06
   |   
Countries: 
   |   
Clinical Sites: 
Full Title: P2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants “VESTED”: V irologic E fficacy and S afety of ART Combinations with T AF/TDF, E FV, and D...

P2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with OBR for MDR-TB in HIV-Infected and Uninfected Children with MDR-TB

Post Date: 
2018-06-07
   |   
Countries: 
   |   
Clinical Sites: 
New study will characterize the pharmacokinetics of delamanid using a model-based approach, and evaluate safety and tolerability of over 24 weeks of study treatment in HIV infected and uninfected children.

A5302: BioBank for Surrogate Marker Research for TB (B-SMART)

Post Date: 
2017-11-21
   |   
Countries: 
   |   
Clinical Sites: 
This study is conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. A5302 is a multi-center trial of the AIDS Clinical Trials Group (ACTG) in collaboration with the Tuberculosis Trials Consortium (TBTC).This study will be conducted at the BJ...

A5332: Randomized Trial to Prevent Vascular Events in HIV – REPRIEVE

Post Date: 
2017-06-09
   |   
Countries: 
   |   
Clinical Sites: 
This study is conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. This is a prospective, double-blind, randomized, placebo-controlled, multicenter efficacy study in 6500 subjects, with individual subjects to be followed for up to 72 months...

A5349: Rifapentine-containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-label, Controlled Phase 3 Clinical Trial

Post Date: 
2017-06-05
   |   
Countries: 
   |   
Clinical Sites: 
This study is conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. This is an international, multicenter, randomized, controlled, open-label, 3-arm, phase 3 non-inferiority trial. Primary Objectives: To evaluate the efficacy of a rifapentine-...

A5300/IMPAACT2003: Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Post Date: 
2015-09-01
   |   
Countries: 
   |   
Clinical Sites: 
This clinical trial was terminated July 18, 2017. It was a study conducted under both the AIDS Clinical Trial Group (ACTG) and the the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network, and funded by the U.S. National Institutes of Health. Dr. Amita Gupta was...

A5290: A Randomized, Phase 2b Study of a Double-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen with Rifampin-Based Tuberculosis Treatment versus a Standard-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen with Rifabutin-Based Tuberculosis...

Post Date: 
2015-07-07
   |   
Countries: 
   |   
Clinical Sites: 
This study was terminated February 23, 2016; it was conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health.. Full Title: A5290, A Randomized, Phase 2b Study of a Double-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen with Rifampin-Based...

Inflammation in HIV-infected Pregnant Women: Relationship with Diet, Gut Microbiome and Preterm Birth

Post Date: 
2014-10-28
   |   
Countries: 
   |   
Clinical Sites: 
This study was terminated May 7, 2018. P regnancy is a state of relative immunosuppression in order to protect the fetus from being rejected. It has also been shown that the Th-1 helper cell response, which is normally necessary for overcoming TB infection, is suppressed in pregnancy. Thus,...

Predictive Value of TB-symptom Screen in HIV-infected and HIV-uninfected Pregnant Women in Pune, India

Post Date: 
2014-10-28
   |   
Countries: 
   |   
Clinical Sites: 
This study was terminated July 17, 2017. This is a cross sectional observational study will be conducted at BJGMC to establish what the predictive value of the WHO TB symptom screen is in pregnant women in India. We hypothesize that the WHO TB symptom screen will have a higher positive predictive...

A5279: Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-infected Individuals with Latent Tuberculosis Infection

Post Date: 
2014-06-30
   |   
Countries: 
   |   
Clinical Sites: 
This study ended April 27, 2015; it was conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. Dr. Amita Gupta was Protocol Co-Vice Chair for this multinational clinical trial being conducted in Botswana, Brazil, Haiti, Kenya, Malawi, Peru,...

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High TB Incidence Settings

Post Date: 
2014-04-01
   |   
Countries: 
   |   
Clinical Sites: 
This is a clinical trial conducted under the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network and funded by the U.S. National Institutes of Health. Dr. Amita Gupta is Protocol Chair for this multinational clinical trial being conducted in Botswana, Haiti, South...

A5288: MULTIOCTAVE, Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure

Post Date: 
2012-07-16
   |   
Countries: 
This is a mult-country clinical trial being conducted in Brazil, Haiti, India, Kenya, Malawi, Peru, South Africa, Thailand, Uganda, and Zambia under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. A5288 is a multi-step, open-label phase IV, prospective,...

A5273: Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT)

Post Date: 
2011-05-12
   |   
Countries: 
   |   
Clinical Sites: 
This study was terminated May 2, 2017; it was conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. This was a multinational clinical trial conducted in Brazil, India, Kenya, Malawi, Peru, South Africa, Tanzania, Thailand, and Zimbabwe. The...

A5282: A Randomized, Phase II Trial to Compare an HPV Test-and-Treat Strategy to a Cytology-Based Strategy for Prevention of CIN 2+ in HIV-Infected Women

Post Date: 
2011-03-15
   |   
Countries: 
Indo-JHU partnership work on this trial was officially terminated September 10, 2018; it was conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. This multi-country trial is being conducted in Botswana, Haiti, India, Malawi, Peru, South Africa...

P1073: Study of Immune Reconstitution Inflammatory Syndrome (IRIS) for International Sites Initiating Highly Active Antiretroviral Therapy (HAART) in Infants and Children < 72 Months of Age

Post Date: 
2010-11-15
   |   
Countries: 
   |   
Clinical Sites: 
This study was terminated April 23, 2015. This was a multi-national study conducted in India, South Africa, and Tanzania under the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network and funded by the U.S. National Institutes of Health. P1073 is a case controlled...

P1077BF: Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)

Post Date: 
2010-02-02
   |   
Countries: 
This multi-country trial is being conducted in India, Malawi, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe, conducted under the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network and funded by the U.S. National Institutes of Health.. 1077BF is a randomized...

P1077FF: Formula Feeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)

Post Date: 
2010-02-02
   |   
Countries: 
This multi-country trial is being conducted in India, Malawi, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe, under the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network and funded by the U.S. National Institutes of Health. 1077FF is a randomized strategy...

A5225: Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis

Post Date: 
2009-04-22
   |   
Countries: 
   |   
Clinical Sites: 
This trial was terminated in March 2015; it was conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. This multi-country study was conducted in India, Kenyam Peru, South Africa, Thailand, Uganda, United States, and Zimbabwe. A5225/HiFLAC is a...

P1070: Dose-Finding and Pharmacogenetic Study of Efavirenz in HIV-Infected and HIV/TB Co-Infected Infants and Children ≥ 3 Months to < 36 Months of Age

Post Date: 
2008-12-05
   |      |   
Clinical Sites: 
This study ended March 10, 2015. This multi-country trial was conducted in India, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe, under the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network and funded by the U.S. National Institutes of Health. Efavirenz (EFV)...

Pages

Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons

Post Date: 
2019-08-15
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
PLOS Medicine
PLOS Medicine: Dr. Amita Gupta and colleagues discuss the scientific and ethical basis for including pregnant and lactation women, children, and HIV+ patients in tuberculosis therapeutic clinical trials.

High prevalence of insulin resistance and occurrence prior to hyperinsulinemia threshold among people living with HIV in Pune, India

Post Date: 
2019-05-21
   |   
Countries: 
Publication: 
Diabetes Metabolic Syndrome: Clinical Research & Reviews
BACKGROUND Diabetes prevalence in HIV is not well characterized for India, despite the high burden of both individual diseases. Epidemiology of insulin resistance (IR): a precursor to diabetes, and its associated risk factors are also poorly understood in Asian Indian people living with HIV (PLHIV...

Willingness to take multidrug-resistant tuberculosis (MDR-TB) preventive therapy among Adult and adolescent household contacts of MDR-TB index cases: an international multi-site cross-sectional study

Post Date: 
2019-03-28
   |   
Countries: 
Publication: 
Clinical Infectious Diseases
Abstract BACKGROUND: Household contacts (HHCs) of individuals with multidrug-resistant tuberculosis (MDR-TB) are at high risk of infection and subsequent disease. There is limited evidence on the willingness of MDR-TB HHCs to take MDR-TB preventive therapy (TPT) to decrease their risk of TB disease...

Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial

Post Date: 
2019-03-20
   |   
Countries: 
Publication: 
HIV Clinical Trials
BACKGROUND: IMPAACT PROMISE 1077BF/FF was a randomized study of antiretroviral therapy (ART) strategies for pregnant and postpartum women with high CD4+ T-cell counts. We describe postpartum outcomes for women in the study who were randomized to continue or discontinue ART after delivery. METHODS:...

Elevated highly sensitive C-reactive protein and d-dimer levels are associated with food insecurity among people living with HIV in Pune, India.

Post Date: 
2019-03-04
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
Public Health Nutrition
Abstract OBJECTIVE: To assess the prevalence and determinants of food insecurity among people living with HIV (PLWH) in Pune, India and its association with biomarkers known to confer increased risks of morbidity and mortality in this population. DESIGN: Cross-sectional analysis assessing food...

Is there a connection between gestational diabetes, human immunodeficiency virus infection, and tuberculosis?

Post Date: 
2019-01-01
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
International Journal of Tuberculosis and Lung Disease
IJTLD article reviews the epidemiology and immunology of gestational diabetes and finds there's a lot we don't know about interactions between diabetes, pregnancy, and tuberculosis in both HIV+/- women

Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300/I2003)

Post Date: 
2018-09-01
   |   
Clinical Sites: 
Publication: 
International Journal of Tuberculosis and Lung Disease
Current guidelines recommend evaluation of the household contacts of individuals with multidrug-resistant tuberculosis; however, implementation of this policy is challenging.

Prevention of HIV-1 transmission through breastfeeding:efficacy of safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high CD4 cell count (IMPAACT PROMISE)

Post Date: 
2018-04-01
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
Journal of Acquired Immune Deficiency Syndromes
BACKGROUND: No randomized trial has directly compared the efficacy of prolonged infant antiretroviral prophylaxis versus maternal antiretroviral therapy (mART) for prevention of mother-to-child transmission throughout the breastfeeding period. SETTING: Fourteen sites in Sub-Saharan Africa and India...

Household food insecurity is associated with low interferon-gamma levels in pregnant Indian women

Post Date: 
2017-07-01
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
International Journal of Tuberculosis and Lung Disease
Objective: To determine the association between household food insecurity and interferon-gamma (IFN-γ) levels in pregnancy. Design: Pregnant women in India were administered the Household Food Insecurity Access Scale (HFIAS) questionnaire and underwent an IFN-γ release assay. Logistic regression...

Cost effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in India

Post Date: 
2016-01-01
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
International Journal of Tuberculosis and Lung Disease
Background: India has a high burden of active tuberculosis (TB) and human immunodeficiency virus (HIV) infection. Pregnancy increases the risks of developing TB in HIV-infected women. Isoniazid preventive therapy (IPT) reduces progression to TB, but may increase costs and hepatotoxicity. The cost-...

Pregnancy is associated with decreased serum isoniazid levels in women living with HIV

Post Date: 
2019-03-07
Gausi K , Denti P, Weisner L, Wallis C, Onyango-Makumbi C, Chipato T, Theron G, Bradford S, Costello D, Browning R, Chakhtoura N, Weinberg A, Montepiedra G, Gupta A and the IMPAACT P1078 (TB APPRISE) Study Group Team. Pregnancy is associated with decreased serum isoniazid levels in women living...

Impact of INH Adherence on TB Incidence and Mortality by Week 96 in ACTG 5274 Trial 

Post Date: 
2017-02-14
   |   
Countries: 
   |   
Clinical Sites: 
Gupta A , Sun X, Miyahara S, Matoga M, Langat D, Riviere C, Bisson C, Kumwenda J, Hosseinipour MC, for the ACTG A5274/REMEMBER Study Team. Impact of INH Adherence on TB Incidence and Mortality by Week 96 in ACTG 5274 Trial. CROI 2017. Seattle, Washington. 2017.

Risk Factors for Death in Advanced HIV-Infected Adults in an Empiric TB Therapy Trial

Post Date: 
2017-02-14
   |   
Countries: 
   |   
Clinical Sites: 
Bisson G, Ramchandani R , Miyahara S, Sun X, Bao J, Gupta A, Hosseinipour MC, Kumwenda J. Risk Factors for Death in Advanced HIV-Infected Adults in an Empiric TB Therapy Trial. CROI 2017. Seattle, Washington. 2017.